Lineage Cell Therapeutics price target lowered to $3 from $5 at Maxim

Maxim lowered the firm’s price target on Lineage Cell Therapeutics (LCTX) to $3 from $5 and keeps a Buy rating on the shares. Sana Biotechnology (SANA), another player in the cell transplant therapeutic space, has announced positive results for its hypoimmune pancreatic islet cell therapy, which represents a positive signal for the space and further validation of the potential for cell transplant therapies like UP421, OpRegen, and OPC1, the analyst tells investors in a research note. The firm adds however that it is reducing its price target to reflect the dilution from the company’s November financing.